Literature DB >> 23652420

Abnormal ghrelin secretion contributes to gastrointestinal symptoms in multiple system atrophy patients.

Tetsutaro Ozawa1, Jun Tokunaga, Musashi Arakawa, Atsushi Ishikawa, Ryoko Takeuchi, Naomi Mezaki, Takeshi Miura, Naoko Sakai, Mariko Hokari, Akari Takeshima, Kota Utsumi, Takashi Kondo, Akio Yokoseki, Masatoyo Nishizawa.   

Abstract

Patients with multiple system atrophy (MSA) often have evidence of compromised gastrointestinal motility. Ghrelin is a gut hormone that influences gastrointestinal motility in humans. The aim of this study was to determine whether ghrelin secretion is affected in MSA patients, and to investigate the relation between ghrelin secretion and gastrointestinal symptoms. Plasma levels of active ghrelin and unacylated ghrelin were measured in patients with MSA (n = 30), other atypical parkinsonian disorders including progressive supranuclear palsy-Richardson syndrome and corticobasal syndrome (n = 24), and control subjects (n = 24) using enzyme-linked immunosorbent assays. Gastrointestinal symptoms were quantified in all subjects using a self-report questionnaire. The ratio of active ghrelin to total ghrelin in the plasma (active ghrelin ratio) was lower in patients with MSA (mean: 8.0 %) than in patients with other atypical parkinsonian disorders (mean: 13.7 %, P = 0.001) and control subjects (mean: 13.9 %, P = 0.001). The active ghrelin ratio was correlated with the severity of gastrointestinal symptoms in MSA (r = -0.5, P = 0.004). Our observations indicate that ghrelin secretion is affected in patients with MSA. The low active ghrelin ratio may contribute to gastrointestinal symptoms in MSA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652420      PMCID: PMC3734593          DOI: 10.1007/s00415-013-6944-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Is there delayed gastric emptying in patients with multiple system atrophy? An analysis using the (13)C-acetate breath test.

Authors:  Yuji Tanaka; Tomohiro Kato; Hiroshi Nishida; Megumi Yamada; Akihiro Koumura; Takeo Sakurai; Yuichi Hayashi; Akio Kimura; Isao Hozumi; Hiroshi Araki; Masahiko Murase; Masahito Nagaki; Hisataka Moriwaki; Takashi Inuzuka
Journal:  J Neurol       Date:  2012-01-05       Impact factor: 4.849

Review 2.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

3.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

4.  Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.

Authors:  A Gambineri; U Pagotto; M Tschöp; V Vicennati; E Manicardi; A Carcello; M Cacciari; R De Iasio; R Pasquali
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 5.  Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia.

Authors:  Bradley F Boeve; Anthony E Lang; Irene Litvan
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

6.  The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans.

Authors:  Christina Maier; Georg Schaller; Barbara Buranyi; Peter Nowotny; Georg Geyer; Michael Wolzt; Anton Luger
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

7.  Olanzapine increases plasma ghrelin level in patients with schizophrenia.

Authors:  Mari Murashita; Ichiro Kusumi; Takeshi Inoue; Yoshito Takahashi; Hiroshi Hosoda; Kenji Kangawa; Tsukasa Koyama
Journal:  Psychoneuroendocrinology       Date:  2005-01       Impact factor: 4.905

8.  Ghrelin immunoreactivity in human plasma is suppressed by somatostatin.

Authors:  Helene Nørrelund; Troels K Hansen; Hans Ørskov; Hiroshi Hosoda; Masayasu Kojima; Kenji Kangawa; Jørgen Weeke; Niels Møller; Jens S Christiansen; Jens Otto L Jørgensen
Journal:  Clin Endocrinol (Oxf)       Date:  2002-10       Impact factor: 3.478

9.  Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy.

Authors:  Ryuji Sakakibara; Takeo Odaka; Tomoyuki Uchiyama; Rhi Liu; Masato Asahina; Kazuya Yamaguchi; Taketo Yamaguchi; Tomoyuki Yamanishi; Takamichi Hattori
Journal:  Mov Disord       Date:  2004-08       Impact factor: 10.338

10.  Effects of estrogen and recombinant human insulin-like growth factor-I on ghrelin secretion in severe undernutrition.

Authors:  Steven Grinspoon; Karen K Miller; David B Herzog; Kelly A Grieco; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  2 in total

1.  Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Authors:  Tomofumi Miura; Shuichi Mitsunaga; Masafumi Ikeda; Izumi Ohno; Hideaki Takahashi; Hidetaka Suzuki; Ai Irisawa; Takeshi Kuwata; Atsushi Ochiai
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

Review 2.  Gastrointestinal dysfunction in the synucleinopathies.

Authors:  Kathryn A Chung; Ronald F Pfeiffer
Journal:  Clin Auton Res       Date:  2020-11-27       Impact factor: 4.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.